We welcome you to share our blog content. We want to connect people with the information they need. We just ask that you link back to the original post and refrain from editing the text. Any questions? Email Barbara Gabriel.
By Deirdre Saulet
Across the summer of 2017, the Oncology Roundtable partnered with the Association of Community Cancer Centers (ACCC) to survey cancer providers across the country to learn about their priorities, challenges, and top opportunities for growth. Over 290 respondents from 209 organizations participated in the survey. Non-teaching community hospitals comprised slightly over half of the respondents, while 21% were teaching hospitals and 16% were academic medical centers. The remaining respondents were independent practices, freestanding centers, and PPS-exempt cancer hospitals.
Survey respondents will receive their individual program-type cohort reports via email in the coming days. The full national report will soon be made available to all ACCC members (member log in will be required). Keep reading for our initial takeaways.
Cost of treatment is the biggest threat to cancer program growth
When asked to identify the top three threats to future cancer program growth, 68% of respondents selected cost of drugs and/or new treatment modalities—clearly the number one threat. In comparison, only 47% selected the next ranked threat, physician alignment around services and program goals. Other top threats include changes in health care coverage, cuts to fee-for-service reimbursement, and shifting reimbursement towards value-based care.
Click on image to enlarge.
Competition increasing for majority of respondents
For the question above, marketplace competition was ranked sixth out of 12 response choices. Despite only 35% of respondents including it as a top-three threat to their growth, the majority of programs indicated that competition has increased in their market across the past two years.
Clinical standardization and drugs are seen as biggest opportunities to save costs
When asked to select the top three opportunities to save costs, respondents overwhelmingly pointed to clinical standardization and drugs.
These two options far outranked all other options—less than 30% of respondents selected the next-ranked options of supplies, capital expenses, and non-clinical staff.
To realize these two top opportunities, nearly 30% of respondents said they are planning to adopt clinical pathways for medical oncology, either vendor sponsored or homegrown, in the next two years.
Programs believe sub-specialists most likely to drive financial gains
To understand how cancer programs rank the profitability of different services, we asked respondents to select the three investment they believed would yield a positive return. Nearly 60% of respondents included increasing the number of sub-specialists, such as gynecologic oncologists and breast surgeons, in their response.
In contrast, only 34% included increasing the number of general oncology physicians, indicating how much potential cancer programs see in physician specialization.
The second-highest ranked investment was marketing, reflecting the trend of cancer patients acting more like consumers and deciding where to receive their care. Next, nearly 36% of respondents ranked specialty pharmacy in their top three. In contrast, only 14% of respondents believe retail pharmacy will yield a return for their program.
In January 2018, ACCC members will be mailed a gatefold publication with Trending Now in Cancer Care survey highlights and key takeaways.